## Advanced Diagnostic Laboratory Tests Under the Medicare CLFS

<table>
<thead>
<tr>
<th>Test Code</th>
<th>Lab Name</th>
<th>Test Name</th>
<th>Test Descriptor</th>
<th>Approval Date</th>
<th>New ADLT Initial Period</th>
<th>Payment Amount for Dates of Service Before Initial Period</th>
<th>Payment Amount for Dates of Service During New ADLT Initial Period</th>
<th>Payment Amount for Dates of Service During New ADLT Initial Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>0172U (Eff. 7/1/2020)</td>
<td>Myriad</td>
<td>myChoice CDx</td>
<td>Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score</td>
<td>12/11/2019</td>
<td>1/1/20-9/30/20</td>
<td>Contractor Priced</td>
<td>$4,040.00</td>
<td></td>
</tr>
<tr>
<td>0090U</td>
<td>Myriad</td>
<td>myPath Melanoma</td>
<td>Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a categorical result (ie, benign, indeterminate, malignant)</td>
<td>9/6/2019</td>
<td>10/1/19-6/30/20</td>
<td>Contractor Priced</td>
<td>$1,950.00</td>
<td></td>
</tr>
<tr>
<td>0080U</td>
<td>Biodesix</td>
<td>BDX-XL2</td>
<td>Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy</td>
<td>5/17/2019</td>
<td>7/1/19-3/31/20</td>
<td>Contractor Priced</td>
<td>$3,520.00</td>
<td></td>
</tr>
<tr>
<td>TBD</td>
<td>Castle Biosciences, Inc.</td>
<td>DecisionDx-Melanoma</td>
<td>TBD</td>
<td>5/17/2019</td>
<td>7/1/19-3/31/20</td>
<td>Contractor Priced</td>
<td>$7,193.00</td>
<td></td>
</tr>
<tr>
<td>81552* (Eff. 1/1/2020) (Previously 0081U)</td>
<td>Castle Biosciences, Inc.</td>
<td>DecisionDx-UM</td>
<td>Oncology (uveal melanoma), mRNA, gene-expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping genes), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis</td>
<td>5/17/2019</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>81538*</td>
<td>Biodesix</td>
<td>Veristrat</td>
<td>Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival (VeriStrat, Biodesix, Inc.)</td>
<td>12/21/2018</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>0037U</td>
<td>Foundation Medicine, Inc.</td>
<td>FoundationOne CDx</td>
<td>Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden</td>
<td>05/18/2018</td>
<td>7/1/18 - 3/31/19</td>
<td>Contractor Priced</td>
<td>$3,500.00</td>
<td></td>
</tr>
</tbody>
</table>

*Existing ADLT